Trial Outcomes & Findings for Spinal Cord Stimulation in Spinal Muscular Atrophy (NCT NCT05430113)
NCT ID: NCT05430113
Last Updated: 2026-03-16
Results Overview
Isometric torque: measure the isometric torque produced by the subject at the hip during hip-flexion. Comparison of SCS-on with SCS-off performance. Success Criteria: ≥20% increased torque production over SCS-off baseline as measured during single-joint isometric torque.
COMPLETED
NA
3 participants
29 days
2026-03-16
Participant Flow
Participant milestones
| Measure |
Spinal Cord Stimulation
All patients will receive FDA-approved percutaneous spinal cord stimulation leads implanted in the epidural (T12-L2 vertebra) space. The leads will be connected to external stimulators (either FDA-approved or human-grade research stimulator with safety features) during research activities. The control arm was not executed, as there was a lack of funding. Therefore, this was a single arm study only implanting the leads into participants with SMA.
|
|---|---|
|
Overall Study
STARTED
|
3
|
|
Overall Study
COMPLETED
|
3
|
|
Overall Study
NOT COMPLETED
|
0
|
Reasons for withdrawal
Withdrawal data not reported
Baseline Characteristics
We reported for each participant the total distance walked at the pre-study assessment.
Baseline characteristics by cohort
| Measure |
Spinal Cord Stimulation
n=3 Participants
All patients will receive FDA-approved percutaneous spinal cord stimulation leads implanted in the epidural (T12-L2 vertebra) space. The leads will be connected to external stimulators (either FDA-approved or human-grade research stimulator with safety features) during research activities.
|
|---|---|
|
Age, Categorical
<=18 years
|
0 Participants
n=3 Participants
|
|
Age, Categorical
Between 18 and 65 years
|
3 Participants
n=3 Participants
|
|
Age, Categorical
>=65 years
|
0 Participants
n=3 Participants
|
|
Sex: Female, Male
Female
|
0 Participants
n=3 Participants
|
|
Sex: Female, Male
Male
|
3 Participants
n=3 Participants
|
|
Motor Function: 6-Minute Walk Test
SMA01
|
519 meter
n=1 Participants • We reported for each participant the total distance walked at the pre-study assessment.
|
|
Motor Function: 6-Minute Walk Test
SMA02
|
72 meter
n=1 Participants • We reported for each participant the total distance walked at the pre-study assessment.
|
|
Motor Function: 6-Minute Walk Test
SMA03
|
126 meter
n=1 Participants • We reported for each participant the total distance walked at the pre-study assessment.
|
|
Motor Function RHS
SMA01
|
64 Score
n=1 Participants • We reported the score independently for each participant.
|
|
Motor Function RHS
SMA02
|
32 Score
n=1 Participants • We reported the score independently for each participant.
|
|
Motor Function RHS
SMA03
|
49 Score
n=1 Participants • We reported the score independently for each participant.
|
PRIMARY outcome
Timeframe: 29 daysPopulation: Isometric hip flexion torque during maximum voluntary contraction was measured using a HUMAC NORM dynamometer. Assistive effects were assessed by comparing SCS-ON vs SCS-OFF within the same session, and therapeutic effects by comparing post-explant vs pre-implant torque. For both assistive and therapeutic analyses, we report the number of participants who achieved a ≥20% increase in hip flexion torque.
Isometric torque: measure the isometric torque produced by the subject at the hip during hip-flexion. Comparison of SCS-on with SCS-off performance. Success Criteria: ≥20% increased torque production over SCS-off baseline as measured during single-joint isometric torque.
Outcome measures
| Measure |
Spinal Cord Stimulation
n=3 Participants
All patients will receive FDA-approved percutaneous spinal cord stimulation leads implanted in the epidural (T12-L2 vertebra) space. The leads will be connected to external stimulators (either FDA-approved or human-grade research stimulator with safety features) during research activities.
|
|---|---|
|
Muscle Weakness
Therapeutic change (pre-study vs post-study)
|
3 Participants
|
|
Muscle Weakness
Assistive change (SCS ON vs SCS OFF)
|
2 Participants
|
PRIMARY outcome
Timeframe: 29 daysSuccess Criteria: no serious adverse event related to the stimulation or intolerable adverse event reported
Outcome measures
| Measure |
Spinal Cord Stimulation
n=3 Participants
All patients will receive FDA-approved percutaneous spinal cord stimulation leads implanted in the epidural (T12-L2 vertebra) space. The leads will be connected to external stimulators (either FDA-approved or human-grade research stimulator with safety features) during research activities.
|
|---|---|
|
Number of Participants With Adverse Events
|
0 Participants
|
SECONDARY outcome
Timeframe: 29 daysPopulation: Therapeutic changes in hip and knee range of motion were assessed by comparing pre- and post-study measurements, and we reported the number of participants meeting the predefined success criteria.
Range of Motion (ROM): Meaningful Change: increase of \>20% of the hip joint (if available) and the knee joint (if available) during SCS against SCS-off as measured by the HUMAC NORM during single-joint isotonic trials.
Outcome measures
| Measure |
Spinal Cord Stimulation
n=3 Participants
All patients will receive FDA-approved percutaneous spinal cord stimulation leads implanted in the epidural (T12-L2 vertebra) space. The leads will be connected to external stimulators (either FDA-approved or human-grade research stimulator with safety features) during research activities.
|
|---|---|
|
Motor Function ROM
Change in Hip Range of Motion During Walking (Pre- vs Post-Study) · Change in Hip Range of Motion During Walking (Pre- vs Post-Study)
|
1 Participants
|
|
Motor Function ROM
Change in Knee Range of Motion During Walking (Pre- vs Post-Study) · Change in Hip Range of Motion During Walking (Pre- vs Post-Study)
|
1 Participants
|
SECONDARY outcome
Timeframe: 29 daysPopulation: We assessed EMG RMS activity of the hip and knee extensors during walking pre-implant and post-explant. Post-explant EMG analysis was possible for 2 of the 3 participants. We report the number of participants with analyzable data who met the prespecified success criterion (\>20% increase in EMG RMS post-explant vs pre-implant);
Muscle activation: measure surface EMGs produced by the subjects during isometric movements of the hip, knee, and ankle in the HUMAC Norm and compare SCS-on with SCS-off performances. Meaningful Change:\<20% EMG RMS compared to SCS-on.
Outcome measures
| Measure |
Spinal Cord Stimulation
n=2 Participants
All patients will receive FDA-approved percutaneous spinal cord stimulation leads implanted in the epidural (T12-L2 vertebra) space. The leads will be connected to external stimulators (either FDA-approved or human-grade research stimulator with safety features) during research activities.
|
|---|---|
|
Muscle Weakness 2
|
2 Participants
|
SECONDARY outcome
Timeframe: 29 daysPopulation: The 6-minute walk test (6MWT) was conducted pre-implant and post-explant. For each participant, change in distance walked was calculated as the post-explant value minus the pre-implant value. We report the number of participants who increased 6MWT distance by ≥24 m.
6 minute walk test: perform the 6-minute walk test with SCS-on and SCS-off and distance between SCS-on and SCS-off is set to 24 m. If not ambulatory, any increased ambulation distance from SCS-off condition.
Outcome measures
| Measure |
Spinal Cord Stimulation
n=3 Participants
All patients will receive FDA-approved percutaneous spinal cord stimulation leads implanted in the epidural (T12-L2 vertebra) space. The leads will be connected to external stimulators (either FDA-approved or human-grade research stimulator with safety features) during research activities.
|
|---|---|
|
Motor Function: 6-Minute Walk Test
|
2 participants
|
SECONDARY outcome
Timeframe: 29 daysPopulation: Fatigability was quantified using a fatigability index, defined as the percent change in walking velocity from the first lap to the last lap of the 6-minute walk test (6MWT). For each participant, therapeutic change was calculated as the difference in fatigability index from pre-study to post-study (post - pre). We report the number of participants who showed a ≥10% decrease in the fatigability index.
Fatigue will be assessed during motor function tests.
Outcome measures
| Measure |
Spinal Cord Stimulation
n=3 Participants
All patients will receive FDA-approved percutaneous spinal cord stimulation leads implanted in the epidural (T12-L2 vertebra) space. The leads will be connected to external stimulators (either FDA-approved or human-grade research stimulator with safety features) during research activities.
|
|---|---|
|
Motor Function: Fatigue
|
3 participants
|
SECONDARY outcome
Timeframe: 29 daysPopulation: We report the change in RHFS score from baseline to post-explant. End-of-study assessments were available for only two participants because SMA01 could not complete the final evaluation due to the explant surgery schedule. We report the number of assessed participants who met the prespecified success criterion, defined as an increase in RHFS score of ≥2 points from baseline.
The Revised Hammersmith Functional Scale is a further refined version of the Hammersmith Functional Motor Scale Extended and includes specific items focused on lower-limb motor control such as hip-flexion, standing and walking a that are particularly relevant for the type III population of study. The scale is a 36 item performance evaluation, with a score range from 0-69 in which higher scores indicate better performance. Meaningful Change: ≥2 point improvement. Compare outcomes between SCS-on and SCS-off. Motor Function Measure 32. The 32 items MFM is often used in trials of neuromuscular disorders, hence it provides a meaningful comparison against outcomes of other trials. Meaningful Change: ≥2 point improvement. Compare outcomes between SCS-on and SCS-off.
Outcome measures
| Measure |
Spinal Cord Stimulation
n=2 Participants
All patients will receive FDA-approved percutaneous spinal cord stimulation leads implanted in the epidural (T12-L2 vertebra) space. The leads will be connected to external stimulators (either FDA-approved or human-grade research stimulator with safety features) during research activities.
|
|---|---|
|
Motor Function RHS
|
1 Participants
|
SECONDARY outcome
Timeframe: 29 daysPopulation: We report the number of participants who reported discomfort/pain ≥ 3/10 on the 1-10 scale
Patients will be asked to provide a score from 1 to 10 where a greater number indicates a greater amount of discomfort for each stimulation configuration. Spinal cord stimulation produces tingling sensations and other type of sensory phenomena. It is important to document that stimulation intensities required to improve motor function remain within a range of non-painful sensations.
Outcome measures
| Measure |
Spinal Cord Stimulation
n=3 Participants
All patients will receive FDA-approved percutaneous spinal cord stimulation leads implanted in the epidural (T12-L2 vertebra) space. The leads will be connected to external stimulators (either FDA-approved or human-grade research stimulator with safety features) during research activities.
|
|---|---|
|
Number of Participants With Discomfort/Pain
|
0 Participants
|
SECONDARY outcome
Timeframe: 29 daysPopulation: The sensorimotor network structure density analysis data were not collected because it required time-matched acquisition during the fMRI session. Collecting both measures in the same visit would have substantially increased scan duration; to minimize participant burden and discomfort, these data were not obtained.
The investigators will perform High-definition Diffusion Weighted Imaging to quantify Fractional Anisotropy as a measurement of axon density in the brain and spinal cord pre and post study.
Outcome measures
| Measure |
Spinal Cord Stimulation
All patients will receive FDA-approved percutaneous spinal cord stimulation leads implanted in the epidural (T12-L2 vertebra) space. The leads will be connected to external stimulators (either FDA-approved or human-grade research stimulator with safety features) during research activities.
|
|---|---|
|
Sensorimotor Network Structure Density
|
0 Participants
|
SECONDARY outcome
Timeframe: 29 daysPopulation: CGI rating was not collected because adding this assessment would have extended study visits. To minimize participant burden and prioritize the prespecified study outcomes, CGI data were not obtained.
The investigators will collect subjects and therapist feedback on how the technology is performing and what they would want to modify using The Clinical Global Impression Scale, a scale of 1-7 where a lower number indicates better performance and a higher number indicates more greatly impacted by their disease.
Outcome measures
| Measure |
Spinal Cord Stimulation
All patients will receive FDA-approved percutaneous spinal cord stimulation leads implanted in the epidural (T12-L2 vertebra) space. The leads will be connected to external stimulators (either FDA-approved or human-grade research stimulator with safety features) during research activities.
|
|---|---|
|
Impression
|
0 Participants
|
SECONDARY outcome
Timeframe: 29 daysPopulation: The sensorimotor network structure integrity analysis data were not collected because it required time-matched acquisition during the fMRI session. Collecting both measures in the same visit would have substantially increased scan duration; to minimize participant burden and discomfort, these data were not obtained.
The investigators will perform High-definition Diffusion Weighted Imaging to quantify Fractional Anisotropy as a measurement of axon integrity in the brain and spinal cord pre and post study.
Outcome measures
| Measure |
Spinal Cord Stimulation
All patients will receive FDA-approved percutaneous spinal cord stimulation leads implanted in the epidural (T12-L2 vertebra) space. The leads will be connected to external stimulators (either FDA-approved or human-grade research stimulator with safety features) during research activities.
|
|---|---|
|
Sensorimotor Network Structure Integrity
|
0 Participants
|
SECONDARY outcome
Timeframe: 29 daysPopulation: Functional MRI (fMRI) sequences were developed to image the lumbosacral spinal cord while participants performed volitional knee flexion and extension. These scans yielded detectable blood-oxygenation-level-dependent (BOLD) signal changes during the motor task within lumbosacral regions associated with knee motor output. We report the number of participants with analyzable data whose task-evoked BOLD signal was statistically significantly higher at post-study than at pre-study.
The investigators will perform resting state and motor-task functional MRI of the brain and spinal cord to quantify neural network activation at rest and during the execution of simple motor task such as leg muscle contraction.
Outcome measures
| Measure |
Spinal Cord Stimulation
n=3 Participants
All patients will receive FDA-approved percutaneous spinal cord stimulation leads implanted in the epidural (T12-L2 vertebra) space. The leads will be connected to external stimulators (either FDA-approved or human-grade research stimulator with safety features) during research activities.
|
|---|---|
|
Sensorimotor Network Function
|
3 Participants
|
SECONDARY outcome
Timeframe: 29 daysPopulation: Motoneuron excitability was assessed using transcranial magnetic stimulation (TMS). Peak-to-peak motor evoked potential (MEP) amplitudes were recorded following single TMS pulses delivered to the leg area of the primary motor cortex. MEP amplitudes were measured at pre-study and post-study sessions. We report the number of participants who showed a statistically significant decrease in MEP peak-to-peak amplitude at post-explant compared with baseline (pre-implant).
The investigators will measure muscle evoked potential consequent to Transcranial Magnetic Stimulation of the cortico-spinal tract to assess integrity of the cortico-spinal tract.
Outcome measures
| Measure |
Spinal Cord Stimulation
n=3 Participants
All patients will receive FDA-approved percutaneous spinal cord stimulation leads implanted in the epidural (T12-L2 vertebra) space. The leads will be connected to external stimulators (either FDA-approved or human-grade research stimulator with safety features) during research activities.
|
|---|---|
|
Cortico-spinal Tract Integrity
|
3 Participants
|
SECONDARY outcome
Timeframe: 29 daysPopulation: Changes in sensory-to-motoneuron synaptic responsiveness were assessed by measuring spinal sensory reflexes evoked by single-pulse of SCS delivered to the lower-limb muscles during the first and last week of the implant period. We report the number of participants with analyzable data who showed no decrease in reflex response over time (i.e., reflex responses were unchanged or increased at the last-week assessment compared with the first-week assessment)
The investigators will measure H-reflexes of leg muscles to quantify excitability of spinal motoneurons to stimulation of primary sensory afferents pre and post-study. Expected Result: Our main scientific hypothesis is that SCS will restore monosynaptic responses of weak spinal motoneurons, thus increasing H-reflex responses pre and post-study.
Outcome measures
| Measure |
Spinal Cord Stimulation
n=3 Participants
All patients will receive FDA-approved percutaneous spinal cord stimulation leads implanted in the epidural (T12-L2 vertebra) space. The leads will be connected to external stimulators (either FDA-approved or human-grade research stimulator with safety features) during research activities.
|
|---|---|
|
Spinal Circuit Excitability
|
3 Participants
|
SECONDARY outcome
Timeframe: 29 daysPopulation: During maximum voluntary contractions, high-density EMG (HD-EMG) was recorded and the signals were decomposed to identify motor unit discharge times. Peak motor unit firing rate was quantified, and we report the number of participants who exhibited a statistically significant increase in peak firing rate post-explant compared with pre-implant.
The investigators will use high-density EMGs on leg muscles to calculate firing rates of single spinal motoneuron discharge during isometric maximal voluntary contractions.
Outcome measures
| Measure |
Spinal Cord Stimulation
n=3 Participants
All patients will receive FDA-approved percutaneous spinal cord stimulation leads implanted in the epidural (T12-L2 vertebra) space. The leads will be connected to external stimulators (either FDA-approved or human-grade research stimulator with safety features) during research activities.
|
|---|---|
|
Motoneuron Firing Rates
|
3 Participants
|
SECONDARY outcome
Timeframe: 29 daysPopulation: During maximum voluntary contractions, high-density EMG (HD-EMG) was recorded and the signals were decomposed to identify motor units. We report the number of participants who showed a statistically significant increase in the number of detected motor units at post-explant compared with pre-implant
The investigators will use high-density EMGs on leg muscles to calculate the number of firing rates of single spinal motoneuron discharge during isometric maximal voluntary contractions.
Outcome measures
| Measure |
Spinal Cord Stimulation
n=3 Participants
All patients will receive FDA-approved percutaneous spinal cord stimulation leads implanted in the epidural (T12-L2 vertebra) space. The leads will be connected to external stimulators (either FDA-approved or human-grade research stimulator with safety features) during research activities.
|
|---|---|
|
Motor Firing Number
|
0 Participants
|
Adverse Events
Spinal Cord Stimulation
Serious adverse events
Adverse event data not reported
Other adverse events
| Measure |
Spinal Cord Stimulation
n=3 participants at risk
All patients will receive FDA-approved percutaneous spinal cord stimulation leads implanted in the epidural (T12-L2 vertebra) space. The leads will be connected to external stimulators (either FDA-approved or human-grade research stimulator with safety features) during research activities.
|
|---|---|
|
General disorders
Fall
|
100.0%
3/3 • Number of events 5 • 29 days
|
Additional Information
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place